The latest round up in the in human papilloma virus vaccine has revealed that Diane M. Harper, a lead researcher in the trials, says giving the drug to 11-year-old girls “is a great big public health experiment” Of course – many of us had already guessed this.
So far, at least twenty-six US states are reported to be considering some form of legislation requiring the new vaccine for younger girls.
The idea is to inoculate them before they become sexually active, since HPV can be spread through sexual intercourse.However, that idea, no matter how good the intentions behind it, is not the right thinking, Harper said. She feels that the enthusiasm to inoculate all these younger girls may very well backfire at the very time they need protection most. This vaccine should not be mandated for 11-year-old girls,” she reiterated. “It’s not been tested in little girls for efficacy. At 11, these girls do not get cervical cancer – they will not know for 25 years if they will get cervical cancer” She feels that the vaccines purpose has been misinterpreted – and miss-marketed – and Harper also feels that too many girls and women who have had the vaccine will develop a false sense of security, believing they are immune to cancer when they are not, and failing to continue with regular cervical screening which is crucial to diagnosing dysplasia before it can develop into cancer.
Reading some of the media reports does give the impression that the vaccine is some sort of Cancer prevention. It does not prevent cancer but can prevent some HPV transmissions. It is remarkable just how more complex this prevention intervention is than the media and drug companies would have us know. I noted that the vaccine has not been tested for efficacy in younger girls. Instead, the effectiveness was “bridged” from the older girls to the younger ones – meaning that Merck assumed that because it proved effective in the older girls, it also would be effective in the younger ones. The actual tests on the younger girls, ages 9 to 15, were only for safety and immune response.
However, there have been more than 40 cases of Guillian-Barre syndrome – a dangerous immune disorder that can cause numbness and paralysis of the muscles reported in girls who have received the HPV vaccine in combination with the meningitis vaccine. Scientists already know that sometimes a vaccine can trigger the syndrome in a subject. To date they are unsure whether this is due to the vaccine combination or the meningitis alone. Harper says, “I want to be able to sleep with myself when I go to bed at night. My concern is still; let’s get women’s health better. It is still a good vaccine. However, let’s be honest. Don’t over-promise.”
Vaccine Autoimmune Project for Research and Education’s summary.
1) Cervical cancer in Illinois is responsible for only about 200 annual deaths and rates have steadily declined. Nearly all cancers are preventable with a simple Pap test at a fraction of the cost of the vaccine. 2) The HPV vaccine is a unique type of vaccine with no prior clinical experience. The potential for benefit is not nearly as great as the potential for widespread harm if mandated for thousands of children.
3) Merck has funded most HPV vaccine clinical trials and the majority authorship of published papers suggests considerable potential for extensive reporting bias. Over 40% of study co-authors are Merck employees and 81% had received money from Merck.
4) Since cancer requires years to develop the effectiveness if the vaccine is totally hypothetical. Even a Merck executive has recently admitted that vaccine efficacy in women under 15 years is unknown.
5) The HPV vaccine suffers a significant adverse reaction rate (90%) as reported in published trials and also in VAERS. There are no long-term safety studies yet over 500 reports of vaccine failures or adverse reactions have already been reported to the FDA. Gardasil contains a large quantity of a neurotoxin, aluminum at doses that are known to cause neurological damage in animals.
6) Targeting 11 year-old girls is unadvisable, since few studies have assessed children this young. Over one-third of all adverse Gardasil vaccine reactions recently reported to VAERS were in children 16 years old or younger.
7) Since influenza kills ten-times as many individuals as cervical cancer yet flu vaccination is not mandated, HPV mandates can’t be just about “saving more lives”.
8) Even the CDC has recently stated that HPV vaccine should NOT be mandated.
I think it would be a tremendous idea for Merck and the medical profession to partake in increased and extensive research of this vaccine before it is unleashed on the female population. How can they talk of Mandatory vaccination when it would appear that research is seriously lacking and which also seems to have been reviewed and reported upon by employees of Merck! There is also a report showing that HPV is actually more prevalent in men. Which I will put up soon.
Yeah-the vaccine should be encouraged more strongly in boys & men than in girls & women.
Yet another case of a multi-billion dollar drug company pushing their product, with effectiveness, side-effects, long-term worth totally unproven. Plus the nice little sexist bonus on the side, no such programme for the males (the carriers).
Pushing a condom programme would be far more effective, to both males and females.
The flu vaccine comparison was an interesting one, and a mandated programme for that would have far more benefit, for the entire population, not just in reduced deaths, but loss of productivity in the workplace.
Once again it proves that pharmaceutical companies are not concerned about women ’s health but rather their sole concern is increasing their enormous profits. Yes, definitely more research needs to be carried out on male bodies since STI’s are primarily passed from male to female within heterosexual activity not the reverse.
I should also add that Harper is a scientist, physician, professor and the director of the Gynecologic Cancer Prevention Research Group at the Norris Cotton Cancer Center at Dartmouth Medical School in New Hampshire.
She has been studying HPV and a possible vaccine for several of the more than 100 strains of HPV for 20 years.
All of her trials have been with subjects ages 15 to 25. In her own practice, Harper believes the ideal way of administering the new vaccine is to offer it to women ages 18 and up. At the time of their first inoculation, they should be tested for the presence of HPV in their system.
If the test comes back negative, then schedule the follow-up series of the three-part shots. But if it comes back positive?
“Then we don’t know squat, because medically we don’t know how to respond to that”
However, yes – this needs mountains of research. Including that HPV seems to be more prevalent in men.
Yeah everyone – major Pharma pushing their wares and the patriarchal medical system just buys it up.
Strange – Those males become invisible as soon as sexual health and/or contraception are under scrutiny – especially when there are big bucks to be made.
Yes stormy – I agree the ‘flu’ comparison gives a whole different perspective.
[...] of course, Sparkle*Matrix – here and [...]